InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（19 笔）
内部人交易记录
首席执行官已披露买入
0
已披露卖出
19
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Explore the complete record of transactions filed by Albers Jeffrey W., 董事长兼首席执行官. Officer active across 3 companies, notably Blueprint Medicines Corp. In total, 59 reports have been logged. Breakdown: 0 buy · 19 sells. Total volume traded: €7.6m. Activity tracked since 12 May 2021. The latest transaction was disclosed on 7 August 2026 (Levée d'options). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Albers Jeffrey W.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报59 总计
5,000 股@ US$10.39Common StockSEC:0001636282-26-000102:0
5,000 股@ US$104.47Common StockSEC:0001636282-26-000102:1
8,000 股@ US$104.38Common StockSEC:0001636282-26-000102:2
10,000 股@ US$104.68Common StockSEC:0001636282-26-000102:3
5,000 股@ US$14.187.2% 占其流量Common StockSEC:0001193125-25-311505:0
5,000 股@ US$10.346.2% 占其流量Common StockSEC:0001193125-25-238130:0
5,000 股@ US$59.189835.3% 占其流量Common StockSEC:0001193125-25-238130:1
5,777 股Common StockSEC:0001104659-25-069377:0
3,902 股@ US$128.125.6% 占其流量Common StockSEC:0001415889-25-018086:0
6,349 股@ US$10.347.4% 占其流量Common StockSEC:0000950170-25-081198:0
5,000 股@ US$36.051.9% 占其流量Common StockSEC:0001415889-25-014862:0
4,350 股@ US$101.024.7% 占其流量Common StockSEC:0001415889-25-014862:1
650 股@ US$101.930.7% 占其流量Common StockSEC:0001415889-25-014862:2
5,766 股@ US$88.806.2% 占其流量Common StockSEC:0001415889-25-008211:0
7,500 股@ US$36.053.2% 占其流量Common StockSEC:0001415889-25-008112:0
10,000 股@ US$36.054.5% 占其流量Common StockSEC:0001415889-25-001989:0
5,000 股@ US$36.052.3% 占其流量Common StockSEC:0001415889-25-001507:0
15,000 股@ US$36.056.7% 占其流量Common StockSEC:0001415889-24-029971:0
5,000 股@ US$36.052.2% 占其流量Common StockSEC:0001415889-24-026594:0
5,000 股@ US$102.006.1% 占其流量Common StockSEC:0001415889-24-026594:1
6,700 股@ US$36.763195.7% 占其流量Common StockSEC:0001636282-24-000089:0
300 股@ US$36.434.3% 占其流量Common StockSEC:0001636282-24-000070:0
10,000 股@ US$36.054.2% 占其流量Common StockSEC:0001415889-24-023204:0
5,000 股@ US$10.346.4% 占其流量Common StockSEC:0000950170-24-100660:0
2,242 股0Common StockSEC:0001415889-24-016987:0
59 条申报中的 25 条
About Albers Jeffrey W.
Jeffrey W. Albers is Chief Executive Officer. He has filed 55 filings in total, and across the recent sample of 55 filings between 2021-05-14 and 2025-12-08, sales total 5558213 EUR and the most common transaction type is option exercise. His filings concern Blueprint Medicines Corp, Kymera Therapeutics, Inc. and Spyre Therapeutics, Inc., and his largest recent filings are with Blueprint Medicines Corp.
